Firebrick Pharma Ltd

ASX:FRE (Australia)  
A$ 0.06 (0%) Dec 27
At Loss
P/B:
5.82
Market Cap:
A$ 13.45M ($ 8.36M)
Enterprise V:
A$ 12.62M ($ 7.85M)
Volume:
4.22K
Avg Vol (2M):
57.22K
Trade In:
Volume:
4.22K
At Loss
Avg Vol (2M):
57.22K

Business Description

Description
Firebrick Pharma Ltd is an Australian pharmaceutical developer. It is engaged in the development and commercialization of povidone-iodine (PVP-I) products under the Nasodine brand. Its Nasodine Nasal Spray which is in the commercialization phase, is a broad-spectrum anti-viral spray, designed to be an effective treatment and prevention of respiratory viral infections such as the common cold. In parallel, the company is also engaged in the development of the follow-on Nasodine brand products.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.88
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 17.41
Distress
Grey
Safe
Beneish M-Score 5.86
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year Book Growth Rate -45.5

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 84.25
9-Day RSI 74.08
14-Day RSI 66.79
6-1 Month Momentum % -1.79
12-1 Month Momentum % 10

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.19
Quick Ratio 6.36
Cash Ratio 2.84
Days Inventory 2579.66
Days Sales Outstanding 2007.5
Days Payable 1598.11

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -5
Shareholder Yield % -6.05

Profitability Rank

Name Current Vs Industry Vs History
Gross Margin % -164.29
Operating Margin % -28057.14
Net Margin % -8392.86
FCF Margin % -16750
ROE % -57.04
ROA % -48.07
ROIC % -499.11
ROC (Joel Greenblatt) % -1194.92
ROCE % -57.04

Financials

ASX:FRE's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Firebrick Pharma Ltd Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil A$) 0.014
EPS (TTM) (A$) -0.007
Beta 0
Volatility % 53.9
14-Day RSI 66.79
14-Day ATR (A$) 0.00239
20-Day SMA (A$) 0.05505
12-1 Month Momentum % 10
52-Week Range (A$) 0.045 - 0.11
Shares Outstanding (Mil) 210.11

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Firebrick Pharma Ltd Filings

Filing Date Document Date Form
No Filing Data

Firebrick Pharma Ltd Stock Events

Financials Calendars
Event Date Price(A$)
No Event Data

Firebrick Pharma Ltd Frequently Asked Questions

What is Firebrick Pharma Ltd(ASX:FRE)'s stock price today?
The current price of ASX:FRE is A$0.06. The 52 week high of ASX:FRE is A$0.11 and 52 week low is A$0.05.
When is next earnings date of Firebrick Pharma Ltd(ASX:FRE)?
The next earnings date of Firebrick Pharma Ltd(ASX:FRE) is .
Does Firebrick Pharma Ltd(ASX:FRE) pay dividends? If so, how much?
Firebrick Pharma Ltd(ASX:FRE) does not pay dividend.

Press Release

Subject Date
No Press Release